Johnson & Johnson
Published: 02/04/2026|Last Updated: 11/05/2026
Headquarters: New Brunswick, New Jersey, United States
Website: Visit Website
Therapeutic Areas
- Oncology
- Immunology
- Rare Disease
- General Medicine
Pipeline Overview
Major growth drivers:
- Icotrokinra (JNJ-2113) — An oral targeted peptide intended to block the IL-23 receptor that could become the first approved therapy of its kind, also being investigated for psoriatic arthritis and ulcerative colitis.
- Nipocalimab — Already FDA-approved as Imaavy for generalized myasthenia gravis, with late-stage studies ongoing across multiple immune-mediated conditions.
- HLD-0915 (Halda Therapeutics) — J&J acquired Halda Therapeutics for $3.05 billion in December 2025; Halda’s lead asset HLD-0915, in Phase 2, is designed to strengthen J&J’s long-term position in prostate cancer using its RIPTAC platform.
- STELARA (Ustekinumab) — Stelara has 15 approved ustekinumab biosimilars, making ustekinumab the second most competitive biosimilar market, following adalimumab. Global Stelara sales dropped 14.7% year-over-year to roughly US$2.3 billion in Q4 2024, and for the full 12-month period, Stelara sales slipped around 4.6% to US$10.4 billion.
Latest News
- FDA Advisory Committee Recommends Johnson & Johnson’s DARZALEX FASPRO® for High-Risk Smoldering Multiple Myeloma
- Data From Phase 3 QUASAR Long-term Extension (LTE) Study Shows TREMFYA® (guselkumab) Maintains Sustained Remission in Ulcerative Colitis
- FDA Approves Monthly Dosing for J&J’s Rybrevant Faspro, Marking a New Era in Lung Cancer Treatment
- ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment
- J&J Seeks U.S. FDA Approval to Expand STELARA® Use for Pediatric Ulcerative Colitis
- J&J’s ICOTYDE Icotrokinra Results Confirm Long-Term Skin Clearance in Psoriasis Patients
- J&J’s New Combination Therapy Shows Promising Results in Overcoming Treatment Resistance in First-Line Lung Cancer
- J&J’s Nipocalimab Receives FDA Fast Track Designation for Systemic Lupus Erythematosus
- Janssen Seeks Expanded Approval for Prostate Cancer Drug AKEEGA® in Europe
- Johnson & Johnson Announces FDA Approval of TECVAYLI® Plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
- Johnson & Johnson Announces Landmark Phase 3 Results: TECVAYLI® Reduces Risk of Disease Progression or Death by 71% in Early Relapse Multiple Myeloma
- Johnson & Johnson Announces Landmark TREMFYA Data: 80% of Patients Achieve Sustained Clinical Remission in Ulcerative Colitis Through 3 Years
- Johnson & Johnson Announces Promising Erda-iDRS Results: A Breakthrough in Non-Muscle-Invasive Bladder Cancer Treatment
- Johnson & Johnson Completes $3.05 Billion Acquisition of Halda Therapeutics to Advance Next-Gen Cancer Care
- Johnson & Johnson Launches MENTOR™ MemoryGel™ Breast Implants for Reconstruction Patients
- Johnson & Johnson Reports Promising Dual CAR-T Cell Therapy Data of Large B-cell Lymphoma
- Johnson & Johnson Secures FDA Approval for TRUFILL n-BCA to Treat Chronic Subdural Hematoma
- Johnson & Johnson’s DARZALEX FASPRO® Regimen Shows 95% 4-Year Progression-Free Survival in Newly Diagnosed Myeloma Patients
- Johnson & Johnson’s IMAAVY™ (nipocalimab-aahu) Receives U.S. FDA Approval, a Novel FcRn Blocker for Generalized Myasthenia Gravis Patients
- Johnson & Johnson’s TECVAYLI® Plus DARZALEX FASPRO® Combination Delivers Superior Survival Outcomes in Relapsed/Refractory Multiple Myeloma
- Johnson & Johnson’s Akeega® Moves Closer to EMA Approval for High-Risk Metastatic Prostate Cancer
- Johnson & Johnson’s Imaavy Wins European Commission Approval for Generalized Myasthenia Gravis
- Johnson and Johnson’s Groundbreaking Study Shows New Drug Combination Significantly Extends Survival for Asian Lung Cancer Patients
- STELARA® (ustekinumab) for Pediatric Crohn’s Disease: Johnson & Johnson Files for FDA Approval
- U.S. FDA Approves Johnson & Johnson’s INLEXZO™ (gemcitabine intravesical system), a Groundbreaking Bladder-Sparing Treatment for a High-Risk Form of Bladder Cancer
- U.S. FDA Approves Johnson & Johnson’s SIMPONI® (golimumab) for Pediatric Ulcerative Colitis
- U.S. FDA Approves Johnson & Johnson’s TREMFYA® (guselkumab) Subcutaneous Induction for Adults with Ulcerative Colitis
- Johnson & Johnson Q1 2026 Results: Financial Growth and Pipeline Breakthroughs
Discover More
